Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

China Accepts Solasia's Filing for Anti-Nausea/Vomiting Patch

publication date: Jun 28, 2018

Tokyo's Solasia Pharma reported China's Center for Drug Evaluation has completed a review of the New Drug Approval filing for Sancuso ®, a granisetron transdermal patch used to treat nausea and vomiting caused by chemotherapy. The CDE accepted the filing and passed it on to the China National Drug Administration for approval. In 2008, Solasia in-licensed China rights to Sancuso, an extended-use product intended to be left in place for five days, from Strakan, a British company. More details....

Stock Symbol: (TSE: 4597)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.